Allison Robbins, CFA

Founder and Managing Director, Green Shoots Consulting, LLC

📍 United States🔄 Updated September 2026💼 3 investments📅 5 years investing🗓 Last invested Mar 2023
VC🌍 United States
3
Total investments
0
Early stage
1
Mid stage
2
Late stage
5y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
Mar 2023
Truly meaningful medicine comes from breakthroughs in deeply understanding patient biology. We are building the world’s leading predictive simulation of patient biology. We will empower the biopharma industry by informing the right experiments that identify and validate disease driving hidden effects.
Angel Investor
Nov 2021
Verge Genomics is a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data. Verge is focused on developing therapeutics for complex diseases with high unmet need, using human genomics from patient disease tissues and machine learning. Verge has created a proprietary all-in-human CONVERGE® platform, featuring one of the field’s largest and most comprehensive databases of multi-omic patient data. The company is led by experienced computational biologists and drug developers who are successfully advancing clinical and preclinical therapeutic programs in various diseases, including ALS and Parkinson’s disease. Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Angel Investor
Aug 2021
At AKUA, were creating a new wave of plant-based cuisine from ocean-farmed kelp: the most sustainable source of food on Earth. We aim to change your perception of sustainable seafood by working with the plants that grow just beyond the shoreline of every coast in the world.
Experience · 8 entries
All (8)
Investments (3)
Founder (1)
2023
Angel Investor
Mar 2023
Truly meaningful medicine comes from breakthroughs in deeply understanding patient biology. We are building the world’s leading predictive simulation of patient biology. We will empower the biopharma industry by informing the right experiments that identify and validate disease driving hidden effects.
2021
Angel Investor
Nov 2021
Verge Genomics is a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data. Verge is focused on developing therapeutics for complex diseases with high unmet need, using human genomics from patient disease tissues and machine learning. Verge has created a proprietary all-in-human CONVERGE® platform, featuring one of the field’s largest and most comprehensive databases of multi-omic patient data. The company is led by experienced computational biologists and drug developers who are successfully advancing clinical and preclinical therapeutic programs in various diseases, including ALS and Parkinson’s disease. Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Angel Investor
Aug 2021
At AKUA, were creating a new wave of plant-based cuisine from ocean-farmed kelp: the most sustainable source of food on Earth. We aim to change your perception of sustainable seafood by working with the plants that grow just beyond the shoreline of every coast in the world.
2016
Investment Consultant (Consultant)
2016
Tullis Health Investors manages a family of funds and investments, each focused exclusively on healthcare. Founded in 1986, Tullis currently manages three funds focused geographically on North America. The Tullis team has broad and deep experience in healthcare investing and a track record of top-quartile performance.
Merck GHI Venture Fund (Consultant)
2016
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
Show all 8 entries ↓
Investment activity
2021–2023 · 3 investments
2021220231
Recent (last 2 years)Earlier